drugset / Trial / NCT01791972

Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)

NCT01791972

Phase 3 Completed 38 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of a single dose (2 inhalations, 180 mcg total) of Albuterol SPIROMAX (90 mcg per inhalation) versus placebo in patients with EIB.

Timeline

Start
2013-03
Primary completion
2013-05
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Salbutamol Unknown 180 ug Inhaled